Voices
Diego A. Díaz-García: Chemoimmunotherapy vs PD-(L)1 monotherapy
Diego A. Díaz-García/X

Diego A. Díaz-García: Chemoimmunotherapy vs PD-(L)1 monotherapy

Diego A. Díaz-García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology, shared a post on X:

“Chemoimmunotherapy vs PD-(L)1 monotherapy.

Tilte: PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression

Authors: Alessandro Di Federico, Samuele Compagno, Francesco Mantuano, Sara Stumpo, Andrea De Giglio, Federica Pecci, Joao V. Alessi, Xinan Wang, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino, Maria A. Pantaleo, Andrea Arfè, Hossein Borghaei, Marina C. Garassino, Federico Cappuzzo, Andrea Ardizzoni, Mark M. Awad, Biagio Ricciuti

Read The Full Article

Diego A. Díaz-García

A meta-analysis of 24 phase III trials (5,546 patients) found superior outcomes with chemoimmunotherapy over PD-(L)1 monotherapy in advanced NSCLC with PD-L1 ≥50%:

  • OS: HR 0.85
  • PFS: HR 0.61

Treatment selection should remain individualized.”

Diego A. Díaz-García

advanced NSCLC Alessandro Di Federico Andrea Ardizzoni Andrea Arfe Andrea De Giglio Barbara Melotti Biagio Ricciuti cancer cancer treatment chemoimmunotherapy chemotherapy clinical trials Diego A. Díaz García Federica Pecci Federico Cappuzzo Francesca Sperandi Francesco Gelsomino Francesco Mantuano Hossein Borghaei immunotherapy Joao V. Alessi Lung cancer Maria A. Pantaleo Marina C. Garassino Mark M. Awad meta-analysis non small cell lung cancer NSCLC OncoDaily Oncology OS overall survival PD-(L)1 Monotherapy PD-L1 PFS phase III trials Precision Oncology progression-free survival Samuele Compagno Sara Stumpo treatment selection Xinan Wang